Delving into the Latest Updates on Hangzhou Bangshun Pharmaceutical Co., Ltd. with Synapse

Overview

Tags

Hemic and Lymphatic Diseases

Other Diseases

Immune System Diseases

Small molecule drug

Disease domain score

A glimpse into the focused therapeutic areas

Technology Platform

Most used technologies in drug development

Targets

Most frequently developed targets

Disease Domain	Count

Hemic and Lymphatic Diseases	1
Neoplasms	1
Immune System Diseases	1
Endocrinology and Metabolic Disease	1

Top 5 Drug Type	Count

Small molecule drug	1

Top 5 Target	Count

JAK2(Tyrosine-protein kinase JAK2)	1

主要目的评价贝泽昔替尼（OB756）片在健康参与者中多次给药的安全性与耐受性。次要目的评价贝泽昔替尼（OB756）片在健康参与者中多次给药的药代动力学特征。评价贝泽昔替尼（OB756）片在健康参与者中多次给药的药效学特征以及剂量/暴露-效应关系

[Translation]

Primary Objective: To evaluate the safety and tolerability of bezacitinib (OB756) tablets after multiple dosing in healthy participants. Secondary Objectives: To evaluate the pharmacokinetic characteristics of bezacitinib (OB756) tablets after multiple dosing in healthy participants. To evaluate the pharmacodynamic characteristics and dose/exposure-response relationship of bezacitinib (OB756) tablets after multiple dosing in healthy participants.

Start Date10 Sep 2026

Sponsor / Collaborator

Hangzhou Bangshun Pharmaceutical Co., Ltd.

ChiCTR2600124544

/ CompletedPhase 3IIT

Bezacitinib Tablet Compared with Best Available Therapy for the Treatment of Polycythemia Vera Resistant or Intolerant to Hydroxyurea (BEWELL-302): An Open-Label, Randomized, Controlled, Multicenter, Phase 3 Study

Start Date07 Mar 2024

Sponsor / Collaborator

Hangzhou Bangshun Pharmaceutical Co., Ltd.

[+1]

CTR20262941

/ Not yet recruitingPhase 1

评价贝泽昔替尼片在JAK抑制剂治疗难治、复发或不耐受的中高危骨髓纤维化患者中有效性和安全性的单臂、开放、多中心Ⅱ期临床研究

[Translation] A single-arm, open-label, multicenter phase II clinical study evaluating the efficacy and safety of bezacitinib tablets in intermediate- to high-risk patients with myelofibrosis who are refractory, relapsed, or intolerant to JAK inhibitors.

主要目的：评价贝泽昔替尼片治疗JAK抑制剂难治/复发/不耐受中高危骨髓纤维化（MF）的脾脏体积缩小有效率次要目的：评价贝泽昔替尼片治疗JAK抑制剂难治/复发/不耐受中高危MF的客观有效率、脾响应、MF相关症状改善等；评价贝泽昔替尼片治疗JAK抑制剂难治/复发/不耐受中高危MF的安全性。

[Translation]

Primary objective: To evaluate the efficacy of bezacitinib tablets in reducing spleen volume in JAK inhibitor-refractory/relapsed/intolerant intermediate-to-high-risk myelofibrosis (MF). Secondary objectives: To evaluate the objective response, splenic response, and improvement of MF-related symptoms of bezacitinib tablets in JAK inhibitor-refractory/relapsed/intolerant intermediate-to-high-risk MF; and to evaluate the safety of bezacitinib tablets in treating JAK inhibitor-refractory/relapsed/intolerant intermediate-to-high-risk MF.

Start Date-

Sponsor / Collaborator

Hangzhou Bangshun Pharmaceutical Co., Ltd.

100 Clinical Results associated with Hangzhou Bangshun Pharmaceutical Co., Ltd.

Login to view more data

0 Patents (Medical) associated with Hangzhou Bangshun Pharmaceutical Co., Ltd.

Login to view more data

100 Deals associated with Hangzhou Bangshun Pharmaceutical Co., Ltd.

Login to view more data

100 Translational Medicine associated with Hangzhou Bangshun Pharmaceutical Co., Ltd.

Login to view more data

Corporation Tree

Boost your research with our corporation tree data.

login

or

view full example data

Boost your research with our corporation tree data.

Pipeline

Pipeline Snapshot as of 13 Nov 2026

The statistics for drugs in the Pipeline is the current organization and its subsidiaries are counted as organizations,Early Phase 1 is incorporated into Phase 1, Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3

NDA/BLA

1

Login to view more data